Press Releases

Celleron Therapeutics Deploys a Digital Pathology Biomarker Platform in Pivotal Colorectal Cancer Clinical Study

Nov 30, 2021

Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption

Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board

Nov 8, 2021

Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics appoints global financier Richard Taylor as new Board Director

Sep 27, 2021

Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the

Celleron Therapeutics announces James Noble as new Board Chairman

Aug 25, 2021

Oxford, August 25, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, today announced that it

Celleron Therapeutics’ CXD101 shows promising clinical results in its China IND programme with partner Nuance Biotech

Jul 6, 2021

Oxford, UK, 6th July 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced encouraging early

Celleron Therapeutics publishes new findings showing immune modulation underpins the anti-cancer effects of zabinostat

Apr 2, 2021

Oxford, April 2nd, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, has worked closely with

Celleron’s Chief Medical Officer David Kerr to Deliver Guest Presentation at WuXi Healthcare Forum 2021

Mar 1, 2021

Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by

Celleron Therapeutics announces approval of China IND Registration Clinical Trial with partner Nuance Biotech

Jan 20, 2021

Oxford, UK, 20 January 2021 – Celleron Therapeutics, the Oxford-based UK company developing novel medicines to treat cancer, today announced that

Celleron Therapeutics Spins Out SynOx Therapeutics which Secures EUR 37M to Develop Emactuzumab

Nov 30, 2020

Oxford, November 30, 2020 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announces the formation of

Celleron Therapeutics presents at the opening ceremony of BIO-FORUM 2020 held in China

Sep 24, 2020

Oxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage